START sub-studies show no differences in lung or neurocognitive function with early or later treatment
START sub-study shows more bone loss with earlier HIV treatment
Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?
Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved
New antiretrovirals and HIV treatment strategies highlighted at ICAAC
WHO guidelines recommend universal antiretroviral treatment, PrEP for those at substantial risk
